SCHEMBL4848191

SCHEMBL4848191

CCOc1cc(COc2nn(Cc3ccccc3)cc2C=O)ccc1OCc1nc(-c2ccco2)oc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
KDM4E B2RXH2 5/20 0.42
LMNA P02545 5/20 0.42
MAPK1 P28482 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
USP2 O75604 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 4/20 0.38
MAPT P10636 4/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
TSHR P16473 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
PPARA Q07869 1/20 0.34
GAA P10253 3/20 0.34
NTSR1 P30989 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850429 0.96 PPARG (0.45) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4850700 0.94 PPARG (0.50) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4844187 0.93 PPARG (0.45) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4846867 0.93 PPARG (0.47) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4850635 0.93 PPARG (0.40) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4852692 0.93 PPARG (0.41) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4848139 0.92 PPARG (0.41) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4849088 0.91 PPARG (0.40) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4852616 0.90 PPARG (0.43) PPARGKDM4ELMNAMAPK1SMN1; SMN2
SCHEMBL4848574 0.88 KDR (0.45) PPARGLMNASMN1; SMN2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885KDM4E 719/4885LMNA 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.